All In Biotech

Drug Trial Radar · NCT02903524

Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

The Efficacy and Safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer :a Randomised Multicentre, Open-label Trial

Last checked: Nov 20, 2026Latest source record: Sep 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 2016

Primary completion

Sep 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Hebei Medical University Fourth HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Conditions

  • Breast Cancer

Interventions

  • Doxorubicin Hydrochloride Liposome injection and cyclophosphamideDrug

  • pirarubicin and cyclophosphamideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pathological complete responseTime frame: until the completion of 4 cycles (each cycle is 21 days) of chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.